The Validity of a New Procedure-Based Definition of Cancer Status in Patients with Breast-, Lung- and Colorectal Cancer in the Danish National Patient Registry

Figures & data

Table 1 Baseline Characteristics

	Breast Cancer		Lung Cancer		Colorectal Cancer
	Active	Non-Active	Active	Non-Active	Active	Non-Active
Total no. of patients	34	166	146	54	93	107
Age at diagnosis, median [IQR]	76.5 [66.2, 83.0]	61 [52, 69]	71 [67, 77]	70 [64.2, 73.8]	74 [69, 82]	71 [63.5, 77.0]
Gender, male, n %	< 3 (-)	< 3 (-)	69 (47.3)	25 (46.3)	41 (44.1)	61 (57.0)
Lifestyle, n (%)
Former smoker	8 (23.5)	37 (22.3)	76 (52.1)	26 (48.1)	44 (47.3)	39 (36.4)
Current smoker	3 (8.8)	36 (21.7)	62 (42.5)	25 (46.3)	15 (16.1)	22 (20.6)
Never smoked	16 (47.1)	86 (51.8)	6 (4.1)	3 (5.6)	32 (34.4)	43 (40.2)
Unknown smoking status	7 (20.6)	7 (4.2)	2 (1.4)	< 3 (-)	< 3 (-)	3 (2.8)
No alcohol	14 (41.2)	54 (32.5)	23 (15.8)	< 3 (-)	17 (18.3)	24 (22.4)
Less than 14 units of alcohol	10 (29.4)	94 (56.6)	83 (56.8)	26 (48.1)	57 (61.3)	64 (59.8)
Over 14 units of alcohol	< 3 (-)	6 (3.6)	15 (10.3)	13 (24.1)	14 (15.1)	16 (15.0)
Unknown alcohol consumption	9 (26.5)	12 (7.2)	25 (17.1)	13 (24.1)	5 (5.4)	3 (2.8)
Family history, n (%)
No family history of cancer	7 (20.6)	53 (31.9)	71 (48.6)	33 (61.1)	34 (36.6)	51 (47.7)
Family history of cancer	5 (14.7)	39 (23.5)	11 (7.5)	5 (9.3)	8 (8.6)	11 (10.3)
Unknown family history	22 (64.7)	74 (44.6)	65 (44.5)	16 (29.6)	51 (54.8)	44 (41.1)
Comorbidities, n, (%)
No comorbidities	14 (41.2)	93 (56.0)	45 (30.8)	15 (27.8)	25 (26.9)	37 (34.6)
Atrial fibrillation/atrial flutter	< 3 (-)	12 (7.2)	14 (9.6)	6 (11.1)	13 (14.0)	10 (9.3)
AMI	< 3 (-)	< 3 (-)	10 (6.8)	3 (5.6)	6 (6.5)	3 (2.8)
Hypertension	19 (55.9)	52 (31.3)	61 (41.8)	32 (59.3)	42 (45.2)	51 (47.7)
Chronic obstructive pulmonary disease	< 3 (-)	9 (5.4)	32 (21.9)	15 (27.8)	11 (11.8)	6 (5.6)
Peripheral arterial disease	< 3 (-)	< 3 (-)	14 (9.6)	3 (5.6)	< 3 (-)	< 3 (-)
Heart failure	< 3 (-)	< 3 (-)	6 (4.1)	5 (9.3)	7 (7.5)	< 3 (-)
Liver disease	< 3 (-)	3 (1.8)	< 3 (-)	< 3 (-)	3 (3.2)	< 3 (-)
Kidney disease	3 (8.8)	< 3 (-)	8 (5.5)	< 3 (-)	5 (5.4)	3 (2.8)
Hypercholesterolemia	6 (17.6)	36 (21.7)	55 (37.7)	21 (38.9)	43 (46.2)	41 (38.3)
Chronic ischemic heart failure	< 3 (-)	< 3 (-)	17 (11.6)	8 (14.8)	10 (10.8)	9 (8.4)
Diabetes	5 (14.7)	13 (7.8)	25 (17.1)	5 (9.3)	8 (8.6)	12 (11.2)
Venous thromboembolism	< 3 (-)	< 3 (-)	6 (4.1)	< 3 (-)	5 (5.4)	< 3 (-)
Ischemic stroke	< 3 (-)	4 (2.4)	8 (5.5)	< 3 (-)	5 (5.4)	8 (7.5)
Haemorrhagic stroke	< 3 (-)	< 3 (-)	< 3 (-)	< 3 (-)	< 3 (-)	< 3 (-)
Stroke	< 3 (-)	3 (1.8)	5 (3.4)	< 3 (-)	3 (3.2)	7 (6.5)

Table 2 Validity of Active Cancer Definition

	Breast Cancer	Lung Cancer	Colorectal Cancer
Sensitivity = TP/(TP+FN)	26/(26 + 8)≈0.76	142/(142 + 4)≈0.97	59/(59 + 34)≈0.63
Specificity = TN/(FP+TN)	162/(4 + 162)≈0.98	40/(14 + 40)≈0.74	94/(13 + 94)≈0.88
PPV = TP/(TP+FP)	26/(26 + 4)≈0.87	142/(142 + 14)≈0.91	59/(59 + 13)≈0.82
NPV = TN/(FN+TN)	162/(8 +162)≈0.95	40/(4 + 40)≈0.91	94/(34 + 94)≈0.73

Figure 1 Flowchart of study cohort.

Note: Created with BioRender.com.

Figure 2 Distribution of active cancer identification method.

Note: Bar chart showing how patients with active cancer were identified during medical chart review.

Figure 3 (A–D) Days after procedure until active cancer diagnosis.

Notes: Histograms showing the number of days after a given patient‘s potentially curative procedure until their active cancer diagnosis. All cancer types, breast cancer, lung cancer, and colorectal cancer.